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Executive summary 
An estimated 226,700 people in Australia are living with chronic hepatitis C. While the 
numbers of people estimated to have been infected with hepatitis C has reduced over 
the past 15 years, the number of people with hepatitis C-related liver disease is 
increasing.  Growing older and duration of infection are significant determinants in the 
progression to cirrhosis amongst people with hepatitis C. There is a lack of social 
research describing the experiences of people with hepatitis C as they grow older. 
Australia’s population is ageing with an increasing number and proportion of people 
over 65. Government programmatic responses to the ageing population are of a health 
promotion approach focussing on maintaining older people’s health and 
independence. Less than five percent of older people in Australia live or will live in 
aged care facilities with a greater emphasis from government policy on keeping people 
at home: home based aged care services will have an increasingly important role into 
the future. 
This qualitative, interview-based research conducted with key clinical, community and 
bureaucratic stakeholders in the Australian hepatitis C sector aimed to identify key 
issues and challenges relating to ageing and hepatitis C to inform future research 
directions. 
While all participants recognised ageing and hepatitis C as a significant issue for 
Australia, they acknowledged that there was a lack of specific services (clinical and/or 
community-based) targeting older people with hepatitis C. The lack of services resulted 
from the limited contact participants had with older people with hepatitis C, and 
participants expressed concern of their limited understanding of the needs of older 
people with hepatitis C. 
The lack of services is compounded by the variety of definitions of ageing between the 
research literature, national policy and stakeholder perspectives. For example, the 
Australia government considers people over 65 years to be “older”, whereas in the 
context of people with hepatitis C, participants described ageing as older than 55 
years. An Australian Injecting & Illicit Drug Users League investigation into ageing in 
2010 describes people who inject drugs who are over 40 years as ageing. 
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During interviews, significant attention was directed towards discussing whether “age” 
is a proxy for “severity of liver disease” or whether there are specific-age related issues 
associated with mild liver disease. Participants acknowledged that older people with 
hepatitis C often experience co-morbidities related to ageing, in addition to 
extrahepatic manifestations of hepatitis C infection, which often complicate the 
management and treatment of hepatitis C. While the clinical management of hepatitis 
C is changing and new treatments promise a shorter treatment course with fewer side 
effects, several clinicians expressed guilt in advising older people to wait for 
interferon-free regimes because of concern about pre-existing comorbidities, while 
being concerned that advising older people to wait for three to five years for the new 
treatments may be too late.  
Older people with hepatitis C are not identified as a priority population nor are their 
needs discussed in the National Hepatitis C Strategy 2010-2013. Therefore, it is not 
surprising that hepatitis C and ageing are not identified as a priority in either the 
national or state health agenda of the aged care sector. In order to articulate the 
impact and issues associated with hepatitis C and ageing, the issue of ageing in 
Australia needs to be examined broadly and the impact of hepatitis C considered in the 
current context. Exploring the needs of people with hepatitis C as they age needs to 
occur as a matter of urgency, as older people with hepatitis C are a hidden population. 
A comprehensive, strategic approach to hepatitis C and ageing is needed to ensure 
that the needs of older people with hepatitis C do not continue to go unrecognised. 
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Background 
Ageing in Australia 
Australia’s population is ageing, with 14% of the population aged 65 years or over. The 
number of people aged over 65 years has increased by 641,000 people or 26% since 
June 2001,1 and by 2050 people aged over 65 years will make up almost 23% of the 
Australian population.1 The issue of ageing is very topical in the general Australian 
community because the “baby boomer” generation (people born between 1945 and 
1965) are growing older and are highlighting the specific needs, services and 
infrastructure required to support people as they age.  
Given the changing demographics, community and government approaches to ageing 
are adapting. People are retiring later in life, as evidenced by the increasing number of 
people still participating in the workforce at the age of 65 years and the federal 
government agenda to increase the official age of retirement.2 The focus of 
state/territory and federal government programmatic responses to ageing is shifting 
towards health promotion for older people.3 Increased longevity and a higher 
proportion of people growing older have reorientated the delivery of services to 
improving nutrition and increasing older people’s physical activity and emotional 
wellbeing. Obviously these health promotion activities will benefit older people with 
hepatitis C and aim to maintain their long term health, thereby supporting their 
independence to live at home for as long as possible.  
It is worth noting that less than five percent of older people in Australia live in 
residential aged care services. Indeed the focus of the federal and state/territory 
governments is to encourage and support older people to remain in their own homes, 
cared for by family and/or friends for as long as possible.  
Hepatitis C in Australia 
In Australia, an estimated 226,700 people are living with chronic hepatitis C, including 
49,500 people with moderate to severe liver disease.4 Although fewer people are 
acquiring hepatitis C than fifteen years ago,5 the number of people with hepatitis C-
related liver disease is increasing due to the “ageing cohort” effect related to the 
higher incidence of injecting drug use-acquired infection in the 1980s and 1990s.6 In 
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addition, the national hepatitis C notification data shows that the number of older 
Australians (aged >50 years) diagnosed with hepatitis C has risen from 13% (2,059) in 
2007 to 18% (2,393) of diagnoses in 2011. In total, 11,569 people aged over 50 years 
have been diagnosed with hepatitis C over the last five years (2007-2011) and it is 
likely that the increasing trend in older people being diagnosed with hepatitis C 
reflects an increase in late diagnoses rather than new infections.  The burden 
associated with hepatitis C and ageing will continue to rise into the future, with 25% of 
all diagnoses (n=14,246) made between 2007 and 2011, occurring in people aged 40-
49 years.  
The lack of symptoms in the early stages of the disease often results in a significant 
delay between the initial infection and diagnosis. Chronic infection typically results in a 
slow progression of liver inflammation and scarring. If left untreated it can 
progressively lead to mild, moderate, or serious liver disease and in some cases, liver 
failure and liver cancer. Up to 25% of people with hepatitis C will spontaneously clear 
the virus. Of the remaining 75% who develop chronic infection, between 10 and 20% 
will go on to develop cirrhosis, or advanced liver disease, and may require a liver 
transplant. In 2011, hepatitis C infection was the underlying cause of liver disease in 
25% of liver transplants.4 Age and duration of infection of greater than 20 years have 
been identified as significant risk factors for the development of advanced fibrosis and 
cirrhosis.7  
Hepatitis C and ageing 
The majority of the evidence exploring hepatitis C and ageing is focused on the clinical 
consequences of long-term infection with hepatitis C such as advanced liver disease 
and liver cancer, and the proposed clinical management strategies, namely antiviral 
treatment. The management and treatment of hepatitis C is currently undergoing a 
dramatic change with the introduction of Direct Acting Antivirals (DAAs), which are 
administered for short durations and include the option of interferon-free regimes and 
medications with fewer side effects. However, the number of people currently 
accessing hepatitis C treatment remains low (approximately two percent) in Australia.8 
Meanwhile the burden of advanced liver disease associated with hepatitis C is 
estimated to double over the next two decades unless hepatitis C treatment uptake is 
increased.9    
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Older people with hepatitis C often present to clinical services for the first time with 
the complications of advanced liver disease, mainly cirrhosis, liver failure and/or liver 
cancer.10 They also experience higher levels of hepatitis C-related morbidity, in 
addition to the health complications associated with the ageing population more 
generally such as diabetes, cancer, hypertension and high cholesterol. The frequent 
morbidity experienced by older people with hepatitis C, along with the significant 
personal, social and financial costs associated with the infection means that hepatitis C 
must be acknowledged as a significant public health issue for the ageing Australian 
population. However, there is no mention of older people with hepatitis C in the 
current iteration of the National Hepatitis C Strategy.11 
While the complex processes associated with ageing and Human Immunodeficiency 
Virus (HIV) have been acknowledged12 the same attention needs to be given to 
understanding what it means to grow older with hepatitis C. North American clinical 
data suggests that the estimated prevalence of hepatitis C cirrhosis and its 
complications will continue to increase through the next decade and will mostly affect 
those older than 60 years of age.13 Further evidence supports the association between 
ageing, duration of infection and the risk of developing liver cancer.14 
Hepatitis C and ageing among people who inject drugs  
Infection with hepatitis C can have a number of negative consequences on an 
individual’s life.11 Apart from the obvious health-related complications, stigma and 
discrimination, social isolation, economic hardship and psychological distress can 
affect a person’s quality of life at any point during their lifespan. People who inject 
drugs, the population most affected by hepatitis C in Australia, are often confronted 
with additional challenges when they grow older with hepatitis C.15 Qualitative 
research conducted by Australian Injecting & Illicit Drug Users League, identified that 
many people who inject drugs did not anticipate or prepare for old age, and were 
surprised to find themselves advancing in years; in addition, they were confronted by 
friends and injecting peers dying of liver disease related to hepatitis C as hepatitis C 
had never been prioritised and/or they experienced systemic barriers and 
discrimination in their attempt to seek hepatitis C medical care.15 
Consistent with the ageing demographic of the general Australian population, the 
proportion of older people who inject drugs is increasing.16,17 Unfortunately, the 
Background 
 
  
 
Hepatitis C and Ageing: a community brief 7 
  
 
 
ageing population of people who inject drugs is not reflected in the Australian National 
Drug Strategy 2010-1518 and which, as Australian Injecting & Illicit Drug Users League 
notes, clearly has a youth focus and emphasises prevention and early intervention 
strategies. 
Despite the increasing diagnoses of hepatitis C amongst Australians aged over 50 years 
and the high proportion of people ageing with the virus after being infected at a young 
age, there has been no research into the social, health and support needs of people 
growing older with hepatitis C. It is worth noting that aside from the AIVL report,15 
previous exploration of the needs of people with hepatitis C,19-22 have not examined 
the potential impact of ageing on the delivery of services or the changing needs of 
people with hepatitis C as they grow older. The omission of ageing from previous 
needs assessments and the National Hepatitis C Strategy is significant because these 
are pivotal documents that direct the activities of community agencies and 
government policy.  
19, 20, 21, 22
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Project aim 
The aim of this study was to explore the perspectives of key clinical, community and 
bureaucratic stakeholders on broad issues resulting from ageing among people with 
hepatitis C, and the challenges, if any that relate to hepatitis C and ageing in order to 
inform future research directions. People with hepatitis C were not specifically 
targeted for inclusion in this project.  
Methods 
The current study used a qualitative methodology to explore the phenomenon of 
ageing and hepatitis C from the perspective of people working in the field of hepatitis 
C. A purposive recruitment strategy was used to identify key stakeholders in the 
hepatitis C clinical, community and government sectors. Participants were recruited 
through the researcher’s professional network and the research organisation’s 
(Australian Research Centre in Sex, Health and Society, La Trobe University) network. 
People working in the following institutions/sectors were approached to be involved in 
the project: 
 Hepatitis Australia and its member organisations 
 the Australian Injecting & Illicit Drug Users League and its member organisations 
 senior clinical service providers involved in caring for people with hepatitis C 
(including medical specialists, GPs with a special interest in hepatitis C and 
hepatology nurses) in Victoria, Queensland, New South Wales and Western 
Australia 
 public health and policy bureaucrats whose work focuses on reducing the impact of 
Blood Borne Viruses (BBVs) 
A Victorian Government aged care policy officer was recruited given their previous 
contact with the research organisation for a study on people with HIV and ageing. 
Data was collected through semi-structured interviews conducted either face-to-face 
or by the telephone. Interviews were electronically recorded for the purposes of 
analysis as a part of the research process. Participants were asked to provide details of 
their professional role and their contact with people with hepatitis C or older 
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Australians, and their observations about hepatitis C and ageing. In particular 
participants were asked:  
1. Are there issues confronting people with hepatitis C as they grow older in 
Australia? 
2. What are the challenges associated with hepatitis C and ageing for your 
work/organisation now, and over the next decade? 
3. From your experience, what are the challenges associated with hepatitis C and 
ageing in the broader Australian experience? 
The data was analysed using thematic analysis techniques.23 The researcher listened to 
the electronic recordings of the interviews to become familiar with the data and 
identify significant themes. Extracts of the interviews were subsequently transcribed 
according to identification of thematic codes. The transcriptions were reviewed and 
the codes confirmed. The codes were subsequently organised into themes and 
interpreted for the purpose of developing this paper. The data was de-identified 
except for profession. 
The study was approved the Human Research Ethics Committee at La Trobe University, 
Melbourne. All participants provided written informed consent prior to participation.
Results 
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Results 
Participants 
In total, 22 interviews were conducted to identify key issues and challenges relating to 
ageing and hepatitis C in order to inform future research directions. Interviewees 
represent professional services including clinical (senior medical specialists (n=3), 
hepatology nurses (n=4) and a general practitioner (GP) with a special interest in 
hepatitis C (n=1)), community sector (hepatitis organisations (n=8) and drug user 
organisations n=2), policy and state government sector (specifically the blood borne 
virus sector n=3) and a ageing sector policy maker (n=1). 
Main findings 
Defining the issue of ageing in the context of hepatitis C 
All of the 22 study participants identified a need for further research into hepatitis C 
and ageing. Three participants highlighted the ageing “baby boomer” generation as 
driving the current interest in identifying the specific needs of older people, and the 
infrastructure and resources required to address the issue broadly in the present and 
the future. One community worker stated: 
Australia has an ageing demographic and there are significant concerns 
generally about planning for the care needs of older Australians and how 
these services can be funded.  
Participants noted that acknowledging the significance of hepatitis C and ageing in 
Australia and gaining appropriate recognition will require key advocates to develop an 
understanding of ageing in the general Australian population. Understanding the 
broader context will assist in identifying the possible barriers and enablers to an 
effective public health response for hepatitis C and ageing. One bureaucrat described 
the need for a significant amount of work to recognise hepatitis C and ageing as a 
public health issue in Australia;   
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Hep C and ageing has not been explored … hep C is still considered a young 
person’s condition, even though people are hitting their 50’s and 60’s with 
advanced disease… 
While most participants believed that issues around hepatitis C and ageing were 
important, the level of contact with older people living with hepatitis C was often 
minimal. Those working in the community sector indicated they had very limited 
contact with older people with hepatitis C. Clinicians reported having contact with a 
small proportion of the ageing cohort given the urgent need for management of 
hepatitis C-related morbidity. The lack of contact with older people with hepatitis C is a 
significant barrier to understanding the care and support needs of older people with 
hepatitis C. As highlighted by a community worker: 
Anecdotally we know that many people diagnosed in the 1990s were given 
messages on diagnosis that would be considered highly inappropriate now, 
such as ‘go home, don’t worry about it, but don’t share your toothbrush.’ It 
is therefore possible that there is a large cohort of people diagnosed with 
hepatitis C who are 20 years older than when they were diagnosed, who 
are not paying attention to their liver health. 
Participants expressed an overwhelming sense of inevitability regarding hepatitis C and 
ageing; based on the epidemiological data previously discussed, specifically the 
distribution of hepatitis C infection that indicates that the burden of liver disease 
attributable to hepatitis C is highest amongst people over 50 years. A community 
worker who works with people who inject drugs highlighted the impact of the delay in 
responding to hepatitis C and ageing as a predictable issue: 
Ageing has to be a significant component of the hepatitis C story 
considering the 20-30 year timeframe to symptoms. I’m dismayed that this 
wasn’t anticipated … until now when it’s hitting us in the face … I have 
several friends who have died … older people with hep C. 
Many participants had considered hepatitis C and ageing in the course of their work, 
but when they were asked to define “ageing” in the context of hepatitis C, participants 
had several responses. Generally, ageing in the context of hepatitis C was loosely 
described as older than 55 years; even though the Commonwealth Government 
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definition of ageing refers to people over the age of 65 years. However, as one medical 
practitioner identified: 
The Commonwealth defines [ageing] as 65 years +, which is all very well; 
but consider people with a chronic health condition and the age goes down 
… 40s is ageing for some people with chronic diseases. 
This comment about ageing beginning at a younger age was acknowledged by the 
Australian Injecting and Illicit Drug Users League in their peer-based consultation15 
which concluded that ageing amongst people who inject drugs commenced at the age 
of 40 years.  
Forty years was the age that we saw things starting to change for people – 
getting older had an impact … 40 years was a point where [clinical] 
interventions would have an impact before it was too late and the ageing 
process had taken a hold. 
The fact there is a disparity of more than 20 years between the Australian Injecting 
and Illicit Drug Users League and the Commonwealth Government’s consensus on 
“ageing” was highlighted by participants as demonstrating the potentially unique and 
contextual circumstances surrounding hepatitis C and ageing. There was agreement on 
the need for evidence to inform the development of a strategic response to hepatitis C 
and ageing in Australia. The dearth of evidence means that the needs of older people 
with hepatitis C remain unrecognised. 
What’s the issue with hepatitis C and ageing?  
All participants identified progression of liver disease as the most obvious concern 
associated with hepatitis C and ageing. Participants articulated a link between hepatitis 
C, ageing, advanced liver disease and liver cancer regardless of their professional 
background. Another common thread which emerged in several of the interviews 
related to the lack of evidence available to guide the policy and research agenda and 
as a consequence it was not clear whether the focus should be on ageing and hepatitis 
C, or the experiences of people with advanced liver disease, or people who have been 
living long term with hepatitis C (the effect of duration of infection).  Each perspective 
addresses a slightly different population, and emphasises a different subset of 
questions regarding an individual’s needs. The inter-relatedness of each of the 
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potential causes of the issues associated with hepatitis C and ageing was articulated by 
one community worker: 
Anyone over 40 years could have had hep C for 20+ years and be at 
increased risk from the complications associated with duration of infection. 
As we know, progression of liver disease starts to escalate dramatically 
after two decades of living with hepatitis C. 
Several participants highlighted the significant clinical and social evidence supporting 
the effect of HIV infection as a precipitant to advanced ageing and suggested there 
needed to be similar research conducted to investigate whether hepatitis C had a 
similar effect. Although no evidence currently exists, several participants highlighted 
the impact of extrahepatic manifestations of hepatitis C on the development of 
significant co-morbidities, which could lead to accelerated ageing. One clinician stated: 
I get the feeling there may be some issues that are specific to older people 
with hepatitis C … this warrants further investigation. 
This perspective merits the question whether “age” is a proxy for “severity of liver 
disease” or whether there are specific-age related issues associated with mild liver 
disease. It appears clear from insights provided by clinical participants that there are 
numerous risk factors and co-morbidities that accompany older people with or without 
hepatitis C. The likelihood of developing co-morbidities such as diabetes, cancer, 
hypertension and high cholesterol increases as people age. In turn, both the co-
morbidities associated with ageing generally and those associated with hepatitis C 
complicate the management of hepatitis C. Several clinicians highlighted the 
complexity of treating older people for hepatitis C, with one stating: 
The reality is that once you get to “that age” you’re more likely to have 
hypertension and cardiac issues etc, and the [hepatitis C] medications are 
not as well tolerated, so we are trying to slip in hep C treatment before they 
hit the 60+ age group. 
Three clinicians were mindful that treating older people for hepatitis C may be a risky 
proposition; as expressed by one participant: 
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We’re just really mindful that by treating older people with hepatitis C we 
could set off a chain reaction of health issues that we may not be able to 
reign back in. 
Another participant identified that older people with hepatitis C were often more 
desperate for clinical management because they realised that they may have missed 
their chance to be treated and potentially be cured of hepatitis C: 
There’s an increased sense of desperation for people in their 60’s, that if 
they don’t do something about [hepatitis C] now … I think it’s related to 
mortality … 10 years ago if you had a 65 year old come in wanting 
treatment with combination therapy … you wouldn’t treat them … you 
wouldn’t touch someone over the age of 65 years! But … we’ve just treated 
a 72 year old, with some trepidation, but they didn’t have a cardiac history 
or any other co-morbidities. 
While recognising that treating hepatitis C in older people was more complex due to 
co-morbidities, there was equal recognition that older people experience other 
psychological effects of living with hepatitis C, which may not be expressed physically. 
A hepatology nurse stated: 
Older patients with hepatitis C are getting more tired. My patients, who are 
over 50 and 60 years, complain of feeling more tired and more “down”. 
They’ve often lived with the disease for longer, emotionally they’re more 
affected. The stress and strain of living with hepatitis C has taken its toll … 
Most of them have been diagnosed for a while, but they’ve only recently 
prioritised their hepatitis C. 
The changing clinical environment has led to significant developments in the treatment 
and management of hepatitis C. Many patients in hepatitis/liver clinics across Australia 
have been advised to wait for the new treatments which promise high response rates 
with fewer side effects. In particular, patients with co-morbidities that may complicate 
the administration of the current treatment regimens are being advised to wait for the 
“better treatment options”. One clinician described their concern that reluctance to 
treat older people with hepatitis C has created a cohort of patients who may never 
have the opportunity to clear the virus: 
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Once you reach that age … probably 70-75 years there are multiple system 
changes which will affect the long standing, underlying liver disease … and 
that’s when we’ll be left saying – it’s too late to give them the present 
drugs, it’s too late for a transplant and we really missed the boat … 
whether there will be a boat of guilty clinicians who perhaps think they 
should’ve treated people earlier, and angry patients who say “for goodness 
sake, you knew I had hep C what’s wrong with you?” 
One community worker reinforced the clinician’s concern: 
Friends of mine have left their run at [hepatitis C] treatment too late, and 
are now asking how come no one told me 5-10 years ago that this was my 
last chance to be treated? They’ve been denied treatment for reasons that 
have been shown to be irrelevant such as they’re still using or they’re older 
… they’ve lost their chance of clearing the virus. 
Finally, there was a shared view amongst clinicians that the new interferon-free 
treatments regimes will solve the problem of hepatitis C in the future. One participant 
stated: 
I hope the issues associated with hep C and ageing become a heck of a lot 
less over the next decade, if we get what we’re being promised – all oral 
agents, 3 month course, 100% success rate.  We could wipe out the hep C 
discussion all together in people with advanced liver disease, even those 
people with advanced liver disease that is too advanced to treat with Peg 
[interferon] and Ribavirin now. 
However, this belief was challenged by several community workers, who 
acknowledged that many of the issues associated with living with hepatitis C are not 
solely related to clinical issues. For example, the isolation and marginalisation 
experienced by many people with hepatitis C that often results in late presentation to 
clinical services and the risk that perceived or actual stigma and discrimination creates 
barriers to accessing support services. One participant explained: 
I find the attitude that the “drugs are going to fix everything” in hepatitis C 
so interesting … I do acknowledge the importance of pharmaceutical 
developments and what might happen when interferon is no longer 
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required, but quite frankly we have existing problems that are not just 
about the drugs (treatments). 
Ageing and hepatitis C amongst people who inject drugs 
Participants acknowledged that there are significant issues for people with hepatitis C 
as they grow older because of the association with injecting drug use. Many of these 
issues are articulated in AIVL’s report into older injecting opioid users in Australia.15 A 
community worker elaborated: 
[Growing old is] hard for people with hepatitis C who have other comorbidities 
when everything is ok in your life.  When you add to that significant levels of 
poverty, unemployment and significant mental health issues, and huge amounts 
of stigma and discrimination ... that’s the picture for people who inject drugs. We 
could see that [ageing and hepatitis C] was an issue that needed to be put on the 
agenda and some very specific measures taken to address it now rather than 
wait until we’ve got bigger problems on our hands. 
Participants who work with people who inject drugs were keen that a range of issues 
were explored in relation to hepatitis C and ageing, and felt that no single research 
organisation would be able to respond to the breadth of questions around ageing that 
need to be addressed. One community worker described their preference for a 
coordinated research response. 
If research into hepatitis C and ageing can progress, it would be great if the 
natural history of ageing and hepatitis C could be identified and explored. 
Then we could answer the question – does hepatitis C accelerate the ageing 
process? Combine this with a better social understanding of the impact of 
hepatitis C, ageing and the impact of the issues associated with drug use 
such as poverty, homelessness and stigma. 
Several community workers discussed that people with hepatitis C were dying 
prematurely as a result of hepatitis C, even compared to a couple of years ago. Late 
presentation to clinical services amongst people who inject drugs living with hepatitis 
C was highlighted as a concern and articulated by a community worker: 
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The reasons for late presentation [to clinical services] needs to be addressed … 
obviously stigma and discrimination are significant issues for PWID (people who 
inject drugs); those daily, attitudinal bits and pieces are really beginning to bite 
and it prevents people from asking for help.  
There was general concern amongst participants that older people who inject drugs 
with hepatitis C are a hidden and isolated group. As a community worker explained, 
drug use in Australia has a youth focus and is associated with the risk taking period 
associated with being young: 
The concept of an older drug user just doesn’t sit well within the scheme of 
things; services are largely constructed around the generalised stereotype 
of a younger rather than older people. 
One participant who was living with hepatitis C articulated the youth focus of injecting 
drug use: 
It’s ok to think you were a bit wild when you were young but somehow 
admitting to once being an IV drug user when you are much older gets 
more difficult. For example, telling the grandkids that their grandmother 
has an IV drug use related illness is tricky. 
The impact of harm reduction strategies such as opioid replacement therapy means 
that people who inject drugs are now reaching old age where previously they may 
have died at a younger age,24 and highlights the inadequacy of the current response to 
ageing for minority groups such as people who inject drugs.  
Where does hepatitis C and ageing “fit” in the broader Australian context? 
Considering that older people with hepatitis C are not identified as a priority 
population or their needs discussed in the National Hepatitis C Strategy, it is not 
surprising that hepatitis C and ageing is not identified as a priority on the national or 
state health agenda. An aged care policy worker clearly articulated: 
Hepatitis C is not on the [state] Department of Health’s agenda regarding 
ageing or growing older. However, HIV is on the agenda, particularly from 
the perspective of the long term side effects of being on HAART.  
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When asked of the most effective way of raising the profile of hepatitis C and ageing, 
this participant suggested that: 
Hepatitis C needed to be framed as a chronic disease which has physical, 
social and emotional effects … in contrast to focusing on the clinical 
perspective. 
While there has been a shift towards framing hepatitis C as a chronic disease in the 
programmatic response of the hepatitis C community sector in Australia, the literature 
exploring hepatitis C and ageing remains firmly entrenched in a clinical framework. It is 
also apparent that there is little research evidence to guide a response.   
Aged-care services and hepatitis C 
The lack of awareness of BBVs, specifically hepatitis C, amongst aged care services staff 
was repeatedly expressed by participants working in the community sector, and by the 
workers responsible for workforce development as a significant concern for older 
people with hepatitis C. One participant explained: 
A lot of aged care staff are uneducated about BBVs, they often don’t want 
to discriminate but do … aged care staff are often not as well educated as 
hospital staff and these types of environments often breed breaches of 
confidentiality, discrimination and lack of privacy. 
Community based staff from hepatitis organisations explained their struggle to access 
home care services for people with hepatitis C, particularly while people are on 
antiviral treatment and experiencing debilitating side effects. With this experience in 
mind, several participants expressed concern that access to home care services for 
people with advanced liver disease or the complications of hepatitis C may also be 
limited.  
While older people are being supported by government policy to stay at home, older 
people with hepatitis C are reported to experience isolation due to family breakdown 
related to past injecting drug use15 and require support that is external to their family 
network. As explained by a community worker:  
We’re starting to get phone calls regarding aged care services – sometimes 
it’s the sibling or the parent, sometimes it’s the consumer themselves, 
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asking are there any aged care services who know about people of this age 
group who inject drugs or are on pharmacotherapies … we haven’t even 
begun to do that type of scoping … I suspect they don’t exist.  
In terms of who is caring for older people with hepatitis C, one clinician acknowledged 
that “I don’t think we’ve got great systems in place to look after older patients in the 
liver clinic”. Most participants identified general practitioners as the default carer of 
older people because no other profession was positioned to implement a holistic 
approach. A senior bureaucrat added: 
There is a lack of medical generalists, so the doctors are all siloed and 
issues such as hep C and ageing are slipping through the cracks. The GP 
becomes critical in this setting, because they are the only health 
professional who cares for the patient “holistically,” not just systems 
focused.  
In addition, one specialist clinician acknowledged that: 
Hepatologists and infectious diseases doctors are not as aware of the needs 
of older patients with hepatitis C. Once you become a specialist, your 
general medical and geriatrics thought processes get turned off; and I don’t 
think we’ve got many clinicians in the hep C treatment arena who are 
geared to thinking about the issues of old age. 
The lack of “clinical responsibility” for older patients with hepatitis C adds to the 
complexity of hepatitis C and ageing in Australia. 
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Conclusions 
This study aimed to ascertain the extent to which clinical, community and bureaucratic 
stakeholders identify hepatitis C and ageing as an issue for their work. Universally, 
hepatitis C and ageing was identified is an important issue requiring further 
investigation.   
Hepatitis C and ageing was considered by participants as an important area for future 
social, clinical and epidemiological research in Australia.  However, the significance of 
hepatitis C and ageing as a public health issue has not been acknowledged by the 
Australian government and is not an issue for the national health agenda. There is a 
clear need for advocacy on hepatitis C and ageing however, there is inadequate data to 
support such advocacy. Therefore, the need for epidemiological, clinical and social 
research on hepatitis C and ageing was viewed as a matter of urgency.  
Participants were mindful of the very limited contact with older people with hepatitis 
C, and were concerned they had a limited understanding of their needs. The gaps in 
knowledge and the foreseeable implications of ageing with chronic liver disease also 
highlighted the urgency to understand the issue in greater detail.  
It is worth noting that previous research exploring the needs of people with hepatitis C 
in Australia19-22 and the various iterations of the National Hepatitis C Strategy11 have 
not specifically acknowledged the impact of ageing. However in 2010, the Australian 
Injecting and Illicit Drug Users League identified the need for greater understanding of 
the impact of ageing on people who inject drugs, a significant proportion of whom are 
also living with hepatitis C. This pivotal report highlights the issues of social isolation, 
stigma and discrimination and other barriers to accessing clinical and community 
services particularly confronting older people who inject drugs. An important finding of 
that report is the deleterious effect of the youth focus of drug policy in Australia and 
its impact on further alienating older people who inject drugs. 
While the current study focused on understanding the perceptions of hepatitis C and 
ageing from the perspective of key community, clinical and bureaucratic stakeholders, 
it is strongly acknowledged that the insight of older people living with hepatitis C is 
needed to inform a broader and more insightful understanding of the issue.22, 19, 21, 20  
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An issue that will require further clarification in future research is distinguishing 
between the impact of ageing and duration of infection. There was much discussion 
amongst participants about age as a proxy for duration of infection and severity of 
liver disease, and whether there were issues associated with hepatitis C and ageing in 
the setting of mild liver disease. Inclusion of older people with hepatitis C in future 
clinical research will assist in addressing this issue. 
A limitation of this study is the lack of involvement of stakeholders working in the aged 
care sector. While significant effort was made to engage with aged care policy workers 
from both Victoria and national non-government and government sectors, participants 
were difficult to recruit due to lack of interest or expertise in hepatitis C. To develop 
relationships for conducting future research, work needs to be done by the hepatitis C 
sector with the aged care sector to ensure that hepatitis C is understood as a chronic 
disease, rather than a clinical or communicable disease. Reframing hepatitis C as a 
chronic disease with physical, social and emotional effects will align it with existing 
Commonwealth health policy, and thus encourage and support meaningful cross-
sectoral engagement between the ageing and BBV sectors.  
Most importantly there is no need to recreate existing services specifically for people 
with hepatitis C. Instead it is critical to understand the context in which older people 
with hepatitis C are living and the support networks and strategies that already exist in 
order to be able to connect them. 
The lack of understanding and potential for hepatitis C-related stigma and 
discrimination amongst workers in residential aged care services towards older people 
with hepatitis C was repeatedly raised as a concern. However, the reality is that a very 
small proportion of older people (less than five percent) live in residential aged care 
services. While there is the need for hepatitis C workforce development for staff of 
residential aged care services, this cannot be to the detriment of developing the 
capacity of home and community care services. As the Australian population ages, 
greater emphasis will be placed on keeping older people at home. 
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Recommendations 
1. A national hepatitis C needs assessment should be conducted to specifically 
explore the needs of older people with hepatitis C and develop an understanding 
of the challenges at the individual, interpersonal, family, community and service 
level. 
2. Future research is needed to explore how best to support GPs and the aged care 
sector workforce to better manage older people with hepatitis C. 
3. Fundamentally, research needs to address whether “age” is a proxy for “severity of 
liver disease” or whether there are specific-aged related issues associated with 
hepatitis C-related mild liver disease. 
4. Epidemiological research is needed to quantify the burden of hepatitis C in older 
Australians and identify the percentage of older people with hepatitis C who 
currently access clinical services and antiviral treatment. 
5. Advocacy for acknowledgement of hepatitis C and ageing as a significant national 
public health issue needs to occur. A flow on effect of such advocacy should be the 
development of national affiliations between the hepatitis C and aged care sectors, 
to allow for collaborative planning and service delivery, acknowledging the needs 
of older people with hepatitis C. 
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